Siglec-15在肿瘤免疫微环境中的表达及意义的研究进展

Research progress in the expression and significance of Siglec-15 in tumor immune microenvironment

阻断程序性细胞死亡-1(PD-1)/PD-1配体1(PD-L1)是最广泛使用的免疫检查点阻断疗法,但PD-1/PD-L1通路在肿瘤免疫逃逸机制中所占比例不到40%,唾液酸结合免疫球蛋白样凝集素15(Siglec-15)虽与PD-L1的同源性超过30%,但Siglec-15的免疫抑制功能独立于PD-1轴。目前国内外对其研究主要集中于Siglec-15在肿瘤免疫微环境(TIME)中的表达及其与预后的关系,本文回顾并总结了Siglec-15在TIME中的表达、预后以及治疗等方面的研究进展,阐述关于Siglec-15研究前景以及研究存在的不足,为Siglec-15进一步的研究奠定基础。

Blocking programmed cell death-1(PD-1)/programmed cell death ligand 1(PD-L1) is the most widely used immune checkpoint blocking therapy,but PD-1/PD-L1 pathway accounts for less than 40% of the tumor immune escape mechanism.Although sialic acid binding Ig-like lectin 15(Siglec-15) has more than 30% homology with PD-L1,the immunosuppressive function of Siglec-15 is independent of PD-1 axis.At present,the research on Siglec-15 at home and abroad mainly focuses on the expression of Siglec-15 in tumor immune microenvironment(TIME) and its relationship with prognosis.This paper reviews and summarizes the research progress of Siglec-15 expression,prognosis and treatment in TIME and expounds the research prospect and shortcomings of Siglec-15,so as to lay a foundation for the further research of Siglec-15.